MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models.

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier (Grand Rapids, MI, USA)

Meeting: 2017 International Congress

Abstract Number: 542

Keywords: Alpha-synuclein, Antidepressants

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: Using preclinical models, assess the potential disease-modifying effects of nortriptyline (NOR) as a treatment in early Parkinson’s disease (PD).

Background: PD and other synucleinopathies are characterized by intracellular inclusions comprised primarily of misfolded, fibrillar α-synuclein (α-syn). One therapeutic strategy to slow disease progression is to reduce the accumulation of toxic α-syn species by preventing misfolding of the native monomeric form of the protein.  Previous work suggests that tricyclic antidepressants (TCAs) may alter disease progression as they are found to reduce neurodegeneration in a preclinical toxin model of parkinsonism.  In a retrospective analysis of data from a cohort of patients with early PD, TCAs were specifically identified as the class of antidepressant medications associated with a significant delay in the need for dopaminergic therapy.

Methods: Interactions between the TCA compound NOR and α-syn were assessed in in vitro aggregation and kinetics assays and in vivo models including primary neuron cultures, transgenic Drosophila and mice, and the rat pre-formed fibril α-synucleinopathy model.

Results: Aggregation and kinetics assays demonstrate that NOR directly binds to monomeric α-syn at physiologically relevant concentrations and reduces the rate of aggregation eight-fold by increasing the rate of monomeric reconfiguration.  In addition, NOR inhibits the accumulation, aggregation and neurotoxicity of α-syn in primary neuron cultures, transgenic Drosophila and mice, and the rat pre-formed fibril α-synucleinopathy model.

Conclusions: These findings suggest that NOR, a compound that has proven to be safe and effective in treating depression, may slow disease progression in synucleinopathies by directly binding to native α-syn, thereby inhibiting formation of toxic conformations of the protein.

To cite this abstract in AMA style:

T. Collier, L. Lapidus, C. Sortwell, C. Justman, P. Lansbury, K. Paumier. The tricyclic antidepressant medication nortriptyline inhibits alpha-synuclein accumulation, aggregation and toxicity in multiple in vitro and in vivo models. [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/the-tricyclic-antidepressant-medication-nortriptyline-inhibits-alpha-synuclein-accumulation-aggregation-and-toxicity-in-multiple-in-vitro-and-in-vivo-models/. Accessed July 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-tricyclic-antidepressant-medication-nortriptyline-inhibits-alpha-synuclein-accumulation-aggregation-and-toxicity-in-multiple-in-vitro-and-in-vivo-models/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley